Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE) has announced a strategic collaboration with Agility Life Sciences and Centrix Pharma Solutions to form an Integrated CMC Partnership, designed to accelerate drug development for global innovator biopharma companies.
The partnership combines Sai Life Sciences’ expertise in API development, Agility’s capabilities in formulation development, and Centrix’s strengths in drug product development and clinical manufacturing. Together, the three firms will provide end-to-end Chemistry, Manufacturing, and Controls (CMC) services, enabling clients to move efficiently from preclinical studies to first-in-human (FIH) trials.
According to the company, the alliance offers unified expertise across the CMC value chain, reducing duplication, cost, and time while enhancing coordination and risk management. Clients will benefit from integrated development plans, a single point of contact for project execution, and faster progression from molecule discovery to medicine delivery.
Krishna Kanumuri, MD & CEO of Sai Life Sciences, stated:
“By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality, and efficiency. This partnership reflects our shared commitment to supporting customers from discovery to clinic and ultimately to patients.”
About the Partners:
- Sai Life Sciences is a global CRDMO serving over 300 pharma and biotech innovators, with facilities in India, the UK, and the US.
- Agility Life Sciences is a UK-based formulation development CDMO recognized for its “Fast Futureproof Formulations” approach.
- Centrix Pharma Solutions specializes in drug product development and clinical manufacturing with a patient-centric, science-driven focus.
Disclaimer: The above information is based on Sai Life Sciences’ official filing with BSE and NSE under SEBI (LODR) Regulation 30 dated October 8, 2025.
